Pancreas Cancer Surveillance Using an Abbreviated MRI
The registry record from ClinicalTrials.gov (public domain): summary, interventions, outcomes and eligibility. Questions are answered only with quotes from this document. Source: ClinicalTrials.gov, retrieved 2026-11-05.
Ongoing
Record metadata
- Phase
- NA
- Status
- Active not recruiting
- Start
- 2020-10-28
- End
- 2027-12-31
- Enrollment
- 200
- Sites
- 1
- Sponsor class
- OTHER
Not in the data yet: a trial card. A one-glance card (population, design, endpoints, result, each tied to a quote) is not built yet. The fields above are registry or bibliographic metadata, not quotes.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you get that instead of a guess.
Source text
Brief summary · public domain (ClinicalTrials.gov) · T1
This study aims to establish a prospective cohort of developing pancreas cancer and surveillance MRI protocol. With the focused surveillance protocol, we perform surveillance for pancreas cancer for five years to estimate the risk of pancreas cancer and the clinical feasibility of the surveillance MRI.
Intervention · public domain (ClinicalTrials.gov) · T1
Diagnostic_Test: Abbreviated PB MRI. Annual non-contrast PB MRI.
Intervention · public domain (ClinicalTrials.gov) · T1
Genetic: Gene mutation test. K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
Intervention · public domain (ClinicalTrials.gov) · T1
Diagnostic_Test: Conventional follow-up. Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
Arm · public domain (ClinicalTrials.gov) · T1
Abbreviated PB MRI (experimental): Short and Focused non-contrast MRI for surveillance
Primary outcome · public domain (ClinicalTrials.gov) · T1
Detection of pancreas cancer. number of detected pancreas cancer (resectable \& BRPC only) in surveillance MRI. Time frame: 1 year after the last surveillance MRI..
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Scan time of abbreviated PB MRI for surveillance. Time frame: 1 month after the first surveillance MRI..
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Estimation of pancreas cancer risk. Time frame: 1 year after the last surveillance MRI..
Secondary outcome · public domain (ClinicalTrials.gov) · T1
Detection of pancreas cancer. Time frame: 1 year after the last surveillance MRI..
Eligibility · public domain (ClinicalTrials.gov) · T1
Inclusion Criteria: * On follow-up due to first degree-family history of PAC * Or on follow-up for BD-IPMN (\>= 2 cm) or main-duct type IPMN (\> 5 mm) * And signed informed consent Exclusion Criteria: * Contra-indication of performing MRI * Not satisfying the selection criteria. * Previously diagnosed with pancreatic malignancy * Pregnancy or planning pregnancy
Enrollment · public domain (ClinicalTrials.gov) · T1
Enrollment: 200 participants (actual).